@official.justin.bucki's peptide therapy claims, fact-checked

What did @official.justin.bucki actually say?

The creator made three specific claims about BPC-157 dosing. First, that an oral capsule form exists as an alternative to injections. Second, that oral BPC-157 requires a higher dose because "your liver will destroy some of it" during first-pass metabolism. Third, that he personally recommends starting at 500 micrograms orally and finds no benefit above 300 micrograms daily via injection, based on his own experimentation with clients and himself.

These are real claims with real implications for people making decisions about an unregulated peptide. Some of it is grounded in plausible biology. Some of it is personal anecdote dressed up as clinical guidance. The difference matters.

Does the science back this up?

Partially, and with significant caveats. The first-pass metabolism argument is biologically reasonable, but the specific numbers given have no peer-reviewed basis. BPC-157 has shown oral bioactivity in animal models, which is actually one of its more interesting properties compared to most peptides.

Sikiric et al. (2018, Current Pharmaceutical Design) documented that BPC-157 retains biological activity when administered orally in rodent studies, which contradicts the idea that the liver simply destroys it wholesale. The peptide appears to resist gastric degradation better than most, possibly due to its proline-rich structure. That said, the jump from rat gastric ulcer models to human optimization dosing is enormous, and no clinical trials have established oral bioavailability figures in humans. The claim that oral dosing requires "a little more" is plausible but the specific 500-microgram figure is not evidence-based. It is extrapolation at best.

What did they get wrong (or right)?

Credit where it is due: the existence of oral BPC-157 preparations is accurate, and the general principle that oral peptides face degradation challenges is sound pharmacology. The first-pass metabolism framing is a reasonable lay explanation, even if it slightly oversimplifies what happens with this particular peptide.

Where this goes sideways is the dose specificity. Saying "start with about 500 micrograms" orally and capping injection benefit at "300 micrograms daily" presents personal experimentation as if it were clinical data. There are no published dose-response studies in humans for BPC-157 by any route. The creator is not citing research, he is citing himself. That is a meaningful distinction when people are making decisions about injecting or ingesting an unregulated compound. The framing also implies a clinical relationship with clients, which raises questions about the context in which this guidance is being offered.

What should you actually know?

BPC-157 is not FDA-approved for any human use. It is not a supplement. Compounded BPC-157 exists in a regulatory gray zone, and the FDA has taken enforcement actions against some compounding pharmacies distributing it. Any dose figures circulating on social media, including these, are based on anecdote, animal research, or community experimentation, not human clinical trials.

The oral versus injectable debate is genuinely interesting from a research standpoint. Pevec et al. (2010, Journal of Physiology-Paris) showed oral BPC-157 produced gut-protective effects in rats, suggesting some bioavailability. But translating that into confident human dosing numbers is not scientifically justified. If you are considering BPC-157 under medical supervision through a regulated telehealth provider, your clinician should be reviewing your specific health context, not applying a social media creator's self-reported dosing ceiling as a starting point.